Worth remembering that AZERCELL is not only being developed for DLBCL but eventually to the targeting of solid tumours with ONCARlytics, don't fall for "the niche market" b/s that gets posted here.
If the oncoming preliminary data for ONCARlytics is just as good this stock will rerate tenfold, IMO.
Add to My Watchlist
What is My Watchlist?